What is Touch Bionics?
Touch Bionics, now operating under the umbrella of Össur Touch Solutions, is a pioneer in the development of sophisticated prosthetic technologies. The company specializes in high-fidelity myoelectric prosthetic hands, partial hand solutions, and hyper-realistic passive silicone prostheses. By integrating advanced sensor technology with ergonomic design, Touch Bionics provides users with enhanced dexterity and a more natural range of motion. Beyond hardware, the firm distinguishes itself through a comprehensive ecosystem of clinical support, specialized training, and patient advocacy resources, ensuring that the transition to prosthetic use is supported by both technical excellence and human-centric care.
How much funding has Touch Bionics raised?
Touch Bionics has raised a total of $11.5M across 4 funding rounds:
Multiple Rounds
$7.7M
Unspecified
$3.9M
Unspecified (2010): $1.3M with participation from Archangels
Debt (2010): $2.5M led by Clydesdale Bank
Other Financing Round (2010): $3.9M supported by Clydesdale Bank
Unspecified (2011): $3.9M featuring Archangel Investors Limited and Scottish Venture Fund
Key Investors in Touch Bionics
Archangels
A prominent business angel syndicate based in Scotland, focusing on early-stage investments in technology and life sciences companies.
Clydesdale Bank
A major UK-based financial institution providing commercial banking and debt financing solutions to support corporate growth and operational stability.
Scottish Venture Fund
A national economic development agency that provides strategic investment to high-growth companies to foster innovation and economic prosperity in Scotland.
What's next for Touch Bionics?
With the support of its recent capital injection, Touch Bionics is well-positioned to accelerate its research and development pipeline, focusing on the next generation of neural-integrated prosthetics. The strategic focus will likely shift toward expanding market penetration in key international territories and refining the user interface of its myoelectric systems. As the demand for high-performance assistive devices grows, the company is expected to leverage its existing clinical partnerships to drive adoption rates. Future growth will be contingent upon the firm's ability to maintain its technological edge while navigating the evolving regulatory landscape of medical devices, ensuring that its product suite remains the gold standard for upper limb rehabilitation.
See full Touch Bionics company page
